Literature DB >> 24177760

High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.

Heather M Walline1, Chris Komarck2, Jonathan B McHugh3, Serena A Byrd4, Matthew E Spector2, Samantha J Hauff5, Martin P Graham2, Emily Bellile6, Jeffrey S Moyer2, Mark E Prince2, Gregory T Wolf2, Douglas B Chepeha2, Francis P Worden7, Matthew H Stenmark8, Avraham Eisbruch8, Carol R Bradford2, Thomas E Carey2.   

Abstract

IMPORTANCE: Human papillomaviruses are now recognized as an etiologic factor in a growing subset of head and neck cancers and have critical prognostic importance that affects therapeutic decision making. There is no universally accepted gold standard for high-risk HPV (hrHPV) assessment in formalin-fixed, paraffin-embedded (FFPE) tissue specimens, nor is there a clear understanding of the frequency or role of hrHPV in sites other than oropharynx.
OBJECTIVE: To determine the optimal assessment of hrHPV in FFPE head and neck tumor tissue specimens. DESIGN, SETTING, PARTICIPANTS: In the setting of a large Midwestern referral center, assessment of hrHPV by p16 immunohistochemical staining, in situ hybridization, and polymerase chain reaction (PCR)-MassArray (PCR-MA), with L1 PGMY-PCR and sequencing to resolve method discordance, was conducted for 338 FFPE oropharyngeal, nasopharyngeal, and oral cavity tumor tissue specimens. Relative sensitivity and specificity were compared to develop a standard optimal test protocol. Tissue specimens were collected from 338 patients with head and neck cancer treated during the period 2001 through 2011 in the departments of Otolaryngology, Radiation Oncology, and Medical Oncology. INTERVENTION: Patients received standard therapy. MAIN OUTCOMES AND MEASURES: Optimal hrHPV identification, detection, and activity in head and neck cancers.
RESULTS: Using combined PCR-MA with L1 PGMY-PCR and sequencing for conclusive results, we found PCR-MA to have 99.5% sensitivity and 100% specificity, p16 to have 94.2% sensitivity and 85.5% specificity, and in situ hybridization to have 82.9% sensitivity and 81.0% specificity. Among HPV-positive tumors, HPV16 was most frequently detected, but 10 non-HPV16 types accounted for 6% to 50% of tumors, depending on the site. Overall, 86% of oropharynx, 50% of nasopharynx, and 26% of oral cavity tumors were positive for hrHPV. CONCLUSIONS AND RELEVANCE: PCR-MA has a low DNA (5 ng) requirement effective for testing small tissue samples; high throughput; and rapid identification of HPV types, with high sensitivity and specificity. PCR-MA together with p16INK4a provided accurate assessment of HPV presence, type, and activity and was determined to be the best approach for HPV testing in FFPE head and neck tumor tissue specimens.

Entities:  

Mesh:

Year:  2013        PMID: 24177760      PMCID: PMC4049419          DOI: 10.1001/jamaoto.2013.5460

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  46 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years.

Authors:  Caroline H Shiboski; Brian L Schmidt; Richard C K Jordan
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

3.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

4.  Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas.

Authors:  J P Klussmann; S J Weissenborn; U Wieland; V Dries; J Kolligs; M Jungehuelsing; H E Eckel; H P Dienes; H J Pfister; P G Fuchs
Journal:  Cancer       Date:  2001-12-01       Impact factor: 6.860

5.  Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples.

Authors:  François Coutlée; Patti Gravitt; Janet Kornegay; Catherine Hankins; Harriet Richardson; Normand Lapointe; Hélène Voyer; Eduardo Franco
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 6.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

7.  HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans.

Authors:  Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Jonathan B McHugh; Kitrina G Cordell; Avraham Eisbruch; Francis P Worden; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jay Stoerker; Heather Walline; Thomas E Carey; Carol R Bradford
Journal:  Head Neck       Date:  2010-05       Impact factor: 3.147

8.  Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; C López-Larrea; C Suárez; M J Menéndez; E Coto
Journal:  Clin Cancer Res       Date:  1995-09       Impact factor: 12.531

9.  Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization.

Authors:  Giuseppe Pannone; Vito Rodolico; Angela Santoro; Lorenzo Lo Muzio; Renato Franco; Gerardo Botti; Gabriella Aquino; Maria Carmela Pedicillo; Simona Cagiano; Giuseppina Campisi; Corrado Rubini; Silvana Papagerakis; Gaetano De Rosa; Maria Lina Tornesello; Franco M Buonaguro; Stefania Staibano; Pantaleo Bufo
Journal:  Infect Agent Cancer       Date:  2012-02-29       Impact factor: 2.965

10.  Does HPV type affect outcome in oropharyngeal cancer?

Authors:  Anthony C Nichols; Sandeep S Dhaliwal; David A Palma; John Basmaji; Corina Chapeskie; Samuel Dowthwaite; Jason H Franklin; Kevin Fung; Keith Kwan; Brett Wehrli; Chris Howlett; Iram Siddiqui; Marina I Salvadori; Eric Winquist; Scott Ernst; Sara Kuruvilla; Nancy Read; Varagur Venkatesan; Biljana Todorovic; J Alex Hammond; James Koropatnick; Joe S Mymryk; John Yoo; John W Barrett
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-02-01
View more
  50 in total

1.  Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population.

Authors:  Lisa A Peterson; Emily L Bellile; Gregory T Wolf; Shama Virani; Andrew G Shuman; Jeremy M G Taylor; Laura S Rozek
Journal:  Head Neck       Date:  2016-07-19       Impact factor: 3.147

2.  Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer.

Authors:  Jeffrey M Vainshtein; Matthew E Spector; Jonathan B McHugh; Ka Kit Wong; Heather M Walline; Serena A Byrd; Christine M Komarck; Mohannad Ibrahim; Matthew H Stenmark; Mark E Prince; Carol R Bradford; Gregory T Wolf; Scott McLean; Francis P Worden; Douglas B Chepeha; Thomas Carey; Avraham Eisbruch
Journal:  Oral Oncol       Date:  2014-02-22       Impact factor: 5.337

Review 3.  HPV and cancer of the oral cavity.

Authors:  Christian U Hübbers; Baki Akgül
Journal:  Virulence       Date:  2015       Impact factor: 5.882

4.  Improving oral human papillomavirus detection using toothbrush sampling in HIV-positive men who have sex with men.

Authors:  Jason J Ong; Tim Read; Marcus Chen; Sandra Walker; Matthew Law; Catriona Bradshaw; Suzanne M Garland; Sepehr N Tabrizi; Alyssa Cornall; Andrew Grulich; Jane Hocking; Christopher K Fairley
Journal:  J Clin Microbiol       Date:  2014-04-09       Impact factor: 5.948

5.  High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV.

Authors:  Heather M Walline; Thomas E Carey; Christine M Goudsmit; Emily L Bellile; Gypsyamber D'Souza; Lisa A Peterson; Jonathan B McHugh; Sara I Pai; J Jack Lee; Dong M Shin; Robert L Ferris
Journal:  Mol Cancer Res       Date:  2016-11-29       Impact factor: 5.852

6.  An Algorithm to Evaluate Suspected Lung Metastases in Patients with HPV-Associated Oropharyngeal Cancer.

Authors:  Kyle K VanKoevering; Emily Marchiano; Heather M Walline; Thomas E Carey; Jonathan B McHugh; J Chad Brenner; Christine M Goudsmit; Emily Belille; Matthew E Spector; Andrew G Shuman
Journal:  Otolaryngol Head Neck Surg       Date:  2017-09-26       Impact factor: 3.497

7.  Association of human papillomavirus integration with better patient outcomes in oropharyngeal squamous cell carcinoma.

Authors:  Lisa M Pinatti; Hana N Sinha; Collin V Brummel; Christine M Goudsmit; Timothy J Geddes; George D Wilson; Jan A Akervall; Chad J Brenner; Heather M Walline; Thomas E Carey
Journal:  Head Neck       Date:  2020-10-19       Impact factor: 3.147

8.  Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.

Authors:  Matthew H Stenmark; Jonathan B McHugh; Matthew Schipper; Heather M Walline; Christine Komarck; Felix Y Feng; Francis P Worden; Gregory T Wolf; Douglas B Chepeha; Mark E Prince; Carol R Bradford; Suresh K Mukherji; Avraham Eisbruch; Thomas E Carey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-01       Impact factor: 7.038

9.  A novel prediction model for human papillomavirus-associated oropharyngeal squamous cell carcinoma using p16 and subcellular β-catenin expression.

Authors:  Guoqing Qian; Zhongliang Hu; Hong Xu; Susan Müller; Dongsheng Wang; Hongzheng Zhang; Sungjin Kim; Zhengjia Chen; Nabil F Saba; Dong M Shin; Andrew Y Wang; Zhuo Georgia Chen
Journal:  J Oral Pathol Med       Date:  2015-10-22       Impact factor: 4.253

10.  Classification of TP53 mutations and HPV predict survival in advanced larynx cancer.

Authors:  Adam Scheel; Emily Bellile; Jonathan B McHugh; Heather M Walline; Mark E Prince; Susan Urba; Gregory T Wolf; Avraham Eisbruch; Francis Worden; Thomas E Carey; Carol Bradford
Journal:  Laryngoscope       Date:  2016-06-27       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.